Aktis Oncology Unveils Miniprotein Radiopharma Platform, Highlights Nectin-4 and B7-H3 Programs



Aktis Oncology (NASDAQ:AKTS) executives outlined the company’s strategy to expand the use of targeted radiopharmaceuticals beyond the limited set of currently approved products, emphasizing a novel “miniprotein” targeting approach, internally built supply chain capabilities, and two lead clinical pr



Source link

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *